Danaher Co. (NYSE:DHR) Declares Quarterly Dividend of $0.27

Danaher Co. (NYSE:DHR) announced a quarterly dividend on Tuesday, May 7th, RTT News reports. Investors of record on Friday, June 28th will be paid a dividend of 0.27 per share by the conglomerate on Friday, July 26th. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 28th.

Danaher has raised its dividend by an average of 13.4% per year over the last three years. Danaher has a dividend payout ratio of 12.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Danaher to earn $8.71 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 12.4%.

Danaher Trading Down 0.1 %

Shares of NYSE:DHR opened at $253.77 on Thursday. The business’s 50 day simple moving average is $255.07 and its 200 day simple moving average is $246.14. The company has a market capitalization of $187.96 billion, a P/E ratio of 43.01, a P/E/G ratio of 3.89 and a beta of 0.85. Danaher has a 1 year low of $182.09 and a 1 year high of $269.11. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.36 EPS. On average, research analysts anticipate that Danaher will post 7.63 EPS for the current fiscal year.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Bank of America raised their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. TD Cowen increased their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Finally, Citigroup increased their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $269.29.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.